We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current TRX market cap is 42.49M. The company's latest EPS is GBP -0.0382 and P/E is -16.10.
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | USD (US$) | GBP (£) | |
| Total Revenue | 11.62M | 13.03M | 12.83M | 19.75M | 24.48M |
| Operating Income | -8.63M | -7.2M | -9.75M | -4.46M | -2.03M |
| Net Income | -8.19M | -6.97M | -9.71M | -4.79M | -2.7M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | USD (US$) | GBP (£) | |
| Total Assets | 37.66M | 30.5M | 36.73M | 46.22M | 46.04M |
| Total Liabilities | 5.09M | 5.9M | 8.88M | 12.83M | 15.64M |
| Total Equity | 32.57M | 24.6M | 27.85M | 33.39M | 30.4M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | USD (US$) | GBP (£) | |
| Operating | -6.84M | -6.68M | -5.23M | -2.98M | -1.29M |
| Investing | -1.9M | -634k | -1.37M | -2.04M | -1.08M |
| Financing | 4k | 1.9M | 13.77M | -192k | 910k |
| Market Cap | 42.49M |
| Price to Earnings Ratio | -16.10 |
| Price to Sales Ratio | 1.77 |
| Price to Cash Ratio | 7.3 |
| Price to Book Ratio | 1.43 |
| Dividend Yield | - |
| Shares Outstanding | 70.57M |
| Average Volume (1 week) | 20.62k |
| Average Volume (1 Month) | 50.34k |
| 52 Week Change | -1.31% |
| 52 Week High | 71.50 |
| 52 Week Low | 49.00 |
| Spread (Intraday) | 1 (1.61%) |
| Company Name | Tissue Regenix Group Plc |
| Address |
unit 3 leeds LS25 2GY |
| Website | https://www.tissueregenix.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
